Reading HUM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HUM free→Reading HUM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HUM free→QuarterlyIQ Insights · HUM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between June 1, 2026 and June 30, 2026. During these meetings, the Company intends to reaffirm its guidance of at least $8.36 in diluted earnings per common share (“EPS”) or at least $9.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2026 (“FY 2026”). This guidance is consistent…
Entry into a Material Definitive Agreement. On May 15, 2026 (the “Closing Date”), pursuant to separate Purchase Agreements, dated May 5, 2026, among Humana Inc. (the “Company”), Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, as representatives of the several initial purchasers, and Horseshoe Funding Trust I (the “2036 Trust”) and Horseshoe Funding Trust II (the “2055 Trust” and, together with the 2036 Tr…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Results of Operations and Financial Condition.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On April 10, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from ten to eleven and elected Robert S. Field as a director of the Company, in each case effective immediately following the adjournment of the Humana Inc. 2026 Annual Meeting of Stockholders on April 16, 2026. The…
Entry into a Material Definitive Agreement. Underwriting Agreement On March 5, 2026, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1.0 billion aggre…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information required by
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 2, 2026 and March 31, 2026. During these meetings, the Company intends to reaffirm its guidance of at least $8.89 in diluted earnings per common share (“EPS”) or at least $9.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2026 (“FY 2026”). This guidance is consisten…
Results of Operations and Financial Condition.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) and (e) On December 16, 2025, Humana Inc. (the “Company”) announced that after a successful 29-year career at the Company, George Renaudin, Insurance Segment President and member of the Company’s Enterprise Leadership Team, will retire by the third quarter of 2026 (the “Transition Date”). Mr. Renaudin has agreed to serve in an advisory capacity…
Regulation FD Disclosure. The Company reaffirms its guidance of approximately $12.26 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is consistent with the guidance issued in the Company’s press release dated November 5, 2025 and Form 8-K filed on December 1, 2025. The Company has included Adjusted EPS in this current report, a financial me…
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between December 1, 2025 and December 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $12.26 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This gui…
Results of Operations and Financial Condition.
Regulation FD Disclosure. Supplementary Audio Commentary Supplementary audio commentary from Humana’s President and Chief Executive Officer, Jim Rechtin, may be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/. 2026 Medicare Advantage Star Ratings Based on preliminary 2026 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which was inadvertently accessible on CMS Plan Finder for a period of time on October 1…
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2025 and September 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $13.77 in diluted earnings per common share (“EPS”) or approximately $17.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This g…
Results of Operations and Financial Condition.
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information described above under
Entry into a Material Definitive Agreement. On May 30, 2025, Humana Inc. (the “Company”) entered into a $5.0 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Bank National Association, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPM…
Results of Operations and Financial Condition.
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information required by
Entry into a Material Definitive Agreement. Underwriting Agreement On March 26, 2025, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters an additional $250 million aggregate principal amount of its 5.375% Senior Notes due 2031 (the “Addi…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information required by
Entry into a Material Definitive Agreement. Underwriting Agreement On March 3, 2025, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BofA Securities, Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and U.S. Bancorp Investments, Inc., as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $750 million aggreg…
Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 3, 2025 and March 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $15.88 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.